HGH 191AA (Somatropin)Growth HormoneSafety Rating 8/10

TypeRecombinant 191-aa growth hormone
CAS12629-01-5
MW22,124 Da
AAs191
Primary research areaGrowth hormone research

Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.

Research dose range0.15–0.3 mg/day SC (adult GHD starting dose)source ↗
AdministrationSubcutaneous injection
Half-life~3–5 hours (SC)
Safety8/10 · FDA-approved (various)
NCAA D1Banned

Price Comparison

Compare vendors

1 vendor competing

VendorPrice$ / IUUpdated
LeoLab RxBest $/IUCOA ✓ · 3P$30.00$3.00May 14, 2026Buy →

Overview

About HGH 191AA

Mechanism of action

Recombinant human growth hormone; binds GHR; activates JAK2/STAT5 pathway; stimulates IGF-1 production; promotes protein synthesis, lipolysis, gluconeogenesis, and bone growth.

Safety profile

Water retention, carpal tunnel, joint pain, insulin resistance, acromegaly (high dose), potential cancer promotion, glucose elevation. · FDA-approved for deficiency; joint pain, edema, insulin resistance at higher doses; cancer surveillance

Storage

Stability & handling

❄️Lyophilized (powder)2–8°Cper labeling (often refrigerated)
💉Reconstituted2–8°Cwithin 14 days
📈

Price tracking starts now.

Set an alert to get notified when this peptide drops.

Safety & Interactions

Contraindications & Drug Interactions

Research use only — not medical advice. Consult a licensed physician before using any peptide. Sources are cited where available.

⚠ CriticalContraindication

Active malignancy — GH is contraindicated in active neoplasia.

⚠ CriticalContraindication

Acute critical illness — increased mortality in ICU patients per FDA warning.

⚠ CriticalContraindication

Prader-Willi patients with severe obesity or sleep apnea — sudden death reports.

Sources: FDA

Related pages

More on HGH 191AA

Stack & Compare

Frequently Researched Together

Research

Studies & key findings

  • Recombinant human GH (somatropin, 191 amino acids identical to pituitary GH) is approved for adult GHD treatment; a 2022 KIMS registry analysis of 15,809 GH-treated patients over a mean 5.3 years confirmed that overall cancer incidence was comparable to the general population, substantially supporting long-term safety for adult replacement therapy.
  • In adults with GHD, somatropin restores normal body composition by reducing fat mass (predominantly visceral) and increasing lean body mass, improves cardiac function, normalizes atherogenic lipid profiles (decreased LDL, increased HDL), and improves quality of life scores — effects confirmed in multiple placebo-controlled trials and systematic review.

6 peer-reviewed sources cited — clinical, preclinical, and regulatory.

Read full research →
Failed to fetch